Cancer vaccine from Moderna, Merck shows promise in late-stage trial; both stocks soar
The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.
The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone. This story matters for Finance & Markets readers tracking bond. Reported by cnbc.com. Read the full original at the source link below.
Originally reported by cnbc.com. BondNews curates and briefs the finance & markets stories that matter. Our editorial policy →